Be Biopharma

We are thrilled to announce that we are now enrolling patients in the BeCoMe-9 Phase I/II trial for people with Hemophilia B. Our mission is to develop transformative medicines that have the potential to improve the lives of people living with rare and prevalent disease, and this milestone brings us one step closer to doing just that.   With the launch of this trial for BE-101, bolstered by fresh capital from our recent $82M funding round, the addition of seasoned clinical and commercial leaders Suha Patel and Kiran C. Patki, MD, MSc, FFPM, and a new development candidate for Hypophosphatasia following closely behind, we are making significant strides toward our goal to improve countless patient stories.   Stay tuned for more updates as we continue this journey!   Read more in our press release: https://lnkd.in/ez6DRUxH. #Hemophilia #ClinicalTrials #Hypophosphatasia #Biotech #Innovation #TransformingLives #BeBio #BCellMedicines

Be Bio’s headed to Italy! We’re excited to share that we’ll be presenting at the European Society of Gene and Cell Therapy (ESGCT) conference in Rome, Oct 22-Oct 25. Join us for the following poster presentations: “Development of precision gene engineered B cells as a treatment for hemophilia B“ “CRISPR/Cas9-based precision B cell gene engineering produces active tissue nonspecific alkaline phosphatase for the potential treatment of hypophosphatasia” Learn more at esgctcongress.com/. See you there! #BeBio #ESCGT

Be Bio proudly participated in the New England Hemophilia Association’s 15th annual Unite for Bleeding Disorders Walk. Through our team’s fundraising efforts, we raised over $9,000 to support local communities. We’re honored to do our part in supporting those living with Hemophilia B as we progress in the development of BE-101. “I am excited to have participated in this event and look forward to upcoming opportunities for the Be Bio team to deepen our connections with the vibrant Hemophilia community." – Joanne Smith-Farrell, Ph.D. #BeBio #HemophiliaB

Join us at the 2024 Cell & Gene Meeting on the Mesa! Hear Be Bio’s CEO Joanne Smith-Farrell’s presentation on Oct 8, 3:30pm ET. We look forward to seeing you there! #MeetingOnTheMesa #BeBio 

ICYMI: Be Bio recently shared new preclinical data for the potential treatment of Hypophosphatasia at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. “This study builds on data presented earlier this year, demonstrating the ability of BCMs to produce sustained active levels of ALP in vivo,” said Rick Morgan, Ph.D. Read the full press release here: https://lnkd.in/g3Aba9UC. #ASBMR #BCellMedicines #BeBio

Join us in Boston! Our CEO Joanne Smith-Farrell will be participating in a panel discussion “Gene and Cell Therapy’s Unlimited Potential” at the World Medical Innovation Forum in Boston, Sept 23 at 11:00am ET. #BeBio #WMIF2024

“Today’s accomplishments were yesterday’s impossibilities.” — Robert Schuller At Be Bio, we take pride in the remarkable achievements of our team, today and every day. As we work toward advancing B Cell medicines and the development of therapies for those in need, we are grateful to our team for the progress we've made. Wishing you a safe and joyful Labor Day! #BeBio #LaborDay

We’re excited to announce the publication of a potential breakthrough in the delivery of bispecific T cell engagers for oncology using B cell medicines (BCMs). In collaboration with our founders at Seattle Children's Research Institute, we have demonstrated that a single dose of BCMs producing an anti-CD3 X anti-CD19 T cell engager effectively treats patient-derived leukemia xenografts in mice. The publication entitled, “Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing” was published in the journal Molecular Therapy and can be found at the link below. https://lnkd.in/ebrxzr4M. #BeBio #Oncology 

Wishing everyone a safe and fun 4th of July! Enjoy the festivities & fireworks. #BeBio #July4th

At Be Bio, we are big believers in celebrating our Pride and support for the LGBTQ+ community not only this month but throughout the year as we build a diverse, inclusive team & culture. #bePROUD